CENTER OVERVIEW

The Center for Human Cell Therapy (CHCT) at the Immune Disease Institute (IDI) was established to provide an infrastructure to rapidly translate novel cell therapy protocols from the laboratory to the clinic. The Center is a cross-institutional effort, drawing its leadership and resources from the following institutions: Children’s Hospital Boston (CHB), Dana-Farber Cancer Institute (DFCI), and Massachusetts General Hospital (MGH) as well as the CBRI. Anchored by its Translational Cell Therapy Laboratory (TransLab) and its Regulatory Core, the Center is designed to provide cell therapy resources for the Harvard community and its affiliated hospitals, from the technical level to the submission of Clinical Protocols and Investigational New Drug applications.

Mission

The mandate of the CHCT is to provide resources to all Harvard Medical School faculty to facilitate bench-to-bedside development of cellular therapies for the treatment of damaged or diseased tissues. Examples of such diseases include the correction of congenital defects and various cancers such as childhood and adult leukemia, prostate and ovarian cancers.

Participating Institutions